Poster
Zenocutuzumab, an antibody that can overcome HER3 mediated NRG1 signaling in tumor cells by docking on HER2
Author
Jan P. Gerlach
Condition
cancer
Drug target
HER2
Drug moa
inhibiting NRG1-mediated HER2:HER3 signaling
Source url
s3://convoke-optic-posters/2024-05-10/Merus_AACR_2021-poster-23Mar21-FINAL.pdf
2 organizations
1 product
Product
ZenocutuzumabOrganization
Crystal and Structural Chemistry, Bijvoet Center for Biomolecular Research, Utrecht UniversityOrganization
Merus